826 related articles for article (PubMed ID: 34135898)
1. The Potential Role of the Intestinal Micromilieu and Individual Microbes in the Immunobiology of Chimeric Antigen Receptor T-Cell Therapy.
Schubert ML; Rohrbach R; Schmitt M; Stein-Thoeringer CK
Front Immunol; 2021; 12():670286. PubMed ID: 34135898
[TBL] [Abstract][Full Text] [Related]
2. How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies.
Hill JA; Seo SK
Blood; 2020 Aug; 136(8):925-935. PubMed ID: 32582924
[TBL] [Abstract][Full Text] [Related]
3. CAR T-Cell Therapy in Hematologic Malignancies: A Voyage in Progress.
Holstein SA; Lunning MA
Clin Pharmacol Ther; 2020 Jan; 107(1):112-122. PubMed ID: 31622496
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies.
Liu J; Zhong JF; Zhang X; Zhang C
J Hematol Oncol; 2017 Jan; 10(1):35. PubMed ID: 28143567
[TBL] [Abstract][Full Text] [Related]
5. Modulation of the gut microbiota engages antigen cross-presentation to enhance antitumor effects of CAR T cell immunotherapy.
Uribe-Herranz M; Beghi S; Ruella M; Parvathaneni K; Salaris S; Kostopoulos N; George SS; Pierini S; Krimitza E; Costabile F; Ghilardi G; Amelsberg KV; Lee YG; Pajarillo R; Markmann C; McGettigan-Croce B; Agarwal D; Frey N; Lacey SF; Scholler J; Gabunia K; Wu G; Chong E; Porter DL; June CH; Schuster SJ; Bhoj V; Facciabene A
Mol Ther; 2023 Mar; 31(3):686-700. PubMed ID: 36641624
[TBL] [Abstract][Full Text] [Related]
6. State of the art in CAR T cell therapy for CD19+ B cell malignancies.
Frigault MJ; Maus MV
J Clin Invest; 2020 Apr; 130(4):1586-1594. PubMed ID: 32235098
[TBL] [Abstract][Full Text] [Related]
7. Anti-CD123 chimeric antigen receptor T-cells (CART): an evolving treatment strategy for hematological malignancies, and a potential ace-in-the-hole against antigen-negative relapse.
Cummins KD; Gill S
Leuk Lymphoma; 2018 Jul; 59(7):1539-1553. PubMed ID: 28901790
[TBL] [Abstract][Full Text] [Related]
8. T-cell-based Immunotherapies for Haematological Cancers, Part B: A SWOT Analysis of Adoptive Cell Therapies.
Rallis KS; Hillyar CRT; Sideris M; Davies JK
Anticancer Res; 2021 Mar; 41(3):1143-1156. PubMed ID: 33788705
[TBL] [Abstract][Full Text] [Related]
9. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.
Grigor EJM; Fergusson D; Kekre N; Montroy J; Atkins H; Seftel MD; Daugaard M; Presseau J; Thavorn K; Hutton B; Holt RA; Lalu MM
Transfus Med Rev; 2019 Apr; 33(2):98-110. PubMed ID: 30948292
[TBL] [Abstract][Full Text] [Related]
10. Advances in Chimeric Antigen Receptor T-Cell Therapies for Solid Tumors.
Baybutt TR; Flickinger JC; Caparosa EM; Snook AE
Clin Pharmacol Ther; 2019 Jan; 105(1):71-78. PubMed ID: 30406956
[TBL] [Abstract][Full Text] [Related]
11. Chimeric antigen receptor-modified T cells: CD19 and the road beyond.
Salter AI; Pont MJ; Riddell SR
Blood; 2018 Jun; 131(24):2621-2629. PubMed ID: 29728402
[TBL] [Abstract][Full Text] [Related]
12. In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas.
Ramos CA; Rouce R; Robertson CS; Reyna A; Narala N; Vyas G; Mehta B; Zhang H; Dakhova O; Carrum G; Kamble RT; Gee AP; Mei Z; Wu MF; Liu H; Grilley B; Rooney CM; Heslop HE; Brenner MK; Savoldo B; Dotti G
Mol Ther; 2018 Dec; 26(12):2727-2737. PubMed ID: 30309819
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of failure of chimeric antigen receptor T-cell therapy.
Li X; Chen W
Curr Opin Hematol; 2019 Nov; 26(6):427-433. PubMed ID: 31577606
[TBL] [Abstract][Full Text] [Related]
14. Chimeric Antigen Receptor T-cell Therapy: Current Status and Clinical Outcomes in Pediatric Hematologic Malignancies.
Talleur AC; Myers R; Annesley C; Shalabi H
Hematol Oncol Clin North Am; 2022 Aug; 36(4):701-727. PubMed ID: 35780062
[TBL] [Abstract][Full Text] [Related]
15. Mucosal-associated invariant T (MAIT) cells, a new source of universal immune cells for chimeric antigen receptor (CAR)-cell therapy.
Bohineust A; Tourret M; Derivry L; Caillat-Zucman S
Bull Cancer; 2021 Oct; 108(10S):S92-S95. PubMed ID: 34920812
[TBL] [Abstract][Full Text] [Related]
16. Toxicities associated with immunotherapies for hematologic malignancies.
Leick MB; Maus MV
Best Pract Res Clin Haematol; 2018 Jun; 31(2):158-165. PubMed ID: 29909916
[TBL] [Abstract][Full Text] [Related]
17. A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy.
Stein-Thoeringer CK; Saini NY; Zamir E; Blumenberg V; Schubert ML; Mor U; Fante MA; Schmidt S; Hayase E; Hayase T; Rohrbach R; Chang CC; McDaniel L; Flores I; Gaiser R; Edinger M; Wolff D; Heidenreich M; Strati P; Nair R; Chihara D; Fayad LE; Ahmed S; Iyer SP; Steiner RE; Jain P; Nastoupil LJ; Westin J; Arora R; Wang ML; Turner J; Menges M; Hidalgo-Vargas M; Reid K; Dreger P; Schmitt A; Müller-Tidow C; Locke FL; Davila ML; Champlin RE; Flowers CR; Shpall EJ; Poeck H; Neelapu SS; Schmitt M; Subklewe M; Jain MD; Jenq RR; Elinav E
Nat Med; 2023 Apr; 29(4):906-916. PubMed ID: 36914893
[TBL] [Abstract][Full Text] [Related]
18. Chimeric antigen receptor therapy in hematological malignancies: antigenic targets and their clinical research progress.
Zhao J; Wu M; Li Z; Su S; Wen Y; Zhang L; Li Y
Ann Hematol; 2020 Aug; 99(8):1681-1699. PubMed ID: 32388608
[TBL] [Abstract][Full Text] [Related]
19. Resistance Mechanisms to CAR T-Cell Therapy and Overcoming Strategy in B-Cell Hematologic Malignancies.
Song MK; Park BB; Uhm JE
Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31658644
[TBL] [Abstract][Full Text] [Related]
20. Chimeric antigen receptor T cells for acute lymphoblastic leukemia.
Frey NV
Am J Hematol; 2019 May; 94(S1):S24-S27. PubMed ID: 30784101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
